You are here: Industry Insights > Alecensa

News List

China approves Roche’s lung cancer drug Alecensa pharmaceutical
August 23, 2018
Roche’s Alecensa (alectinib) drug has secured marketing authorisation from the China National Drug Administration (CNDA) to treat advanced non-small cell lung cancer (NSCLC).
China National Drug Administration grants rapid approval of Roche's Alecensa (alectinib) as a treatment for ALK-positive lung cancer worldpharmanews
August 23, 2018
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the China National Drug Administration (CNDA) has granted marketing authorisation for Alecensa® (alectinib) as a monotherapy treatment for patients with anaplastic lymphoma kinase (ALK)-positive, advanced
Roche's Alecensa receives 'priority review' designation from CNDA biospectrumasia
August 22, 2018
Alecensa is now approved in over 57 countries around the world as an initial (first-line) treatment for ALK-positive advanced NSCLC, including the US, Europe and Japan
EU Follows US and Approves Chugai's ALK Inhibitor "Alecensa®" as First Line Therapy for ALK-Positive biospace
December 22, 2017
Alecensa Now Available in Japan, the United States and Europe for the Treatment of Advanced Lung Cance
Roche granted US approval for wider use of Alecensa pharmatimes
November 08, 2017
Roche group Genentech says its application to expand the use of Alecensa has been approved by US FDA.
Roche’s Alecensa gets green light for early access scheme pharmatimes
September 05, 2017
UK patients with a rare form of lung cancer will be able to access Roche’s Alecensa without the need for prior chemotherapy before official approval is obtained, following its inclusion in the country’s Early Access to Medicines Scheme (EAMS).